These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 8195463)

  • 1. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
    Preskorn SH; Alderman J; Chung M; Harrison W; Messig M; Harris S
    J Clin Psychopharmacol; 1994 Apr; 14(2):90-8. PubMed ID: 8195463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
    Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
    J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting.
    Stock AJ; Kofoed L
    Am J Hosp Pharm; 1994 Sep; 51(18):2279-81. PubMed ID: 7801990
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
    Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
    Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An interaction of sertraline and desipramine.
    Barros J; Asnis G
    Am J Psychiatry; 1993 Nov; 150(11):1751. PubMed ID: 8214190
    [No Abstract]   [Full Text] [Related]  

  • 7. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-drug interactions.
    Preskorn SH
    J Clin Psychiatry; 1996 May; 57(5):223-7. PubMed ID: 8626354
    [No Abstract]   [Full Text] [Related]  

  • 9. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.
    Hamelin BA; Turgeon J; Vallée F; Bélanger PM; Paquet F; LeBel M
    Clin Pharmacol Ther; 1996 Nov; 60(5):512-21. PubMed ID: 8941024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between sertraline and tricyclic antidepressants.
    Lydiard RB; Anton RF; Cunningham T
    Am J Psychiatry; 1993 Jul; 150(7):1125-6. PubMed ID: 8317590
    [No Abstract]   [Full Text] [Related]  

  • 11. [New antidepressive agents].
    LaBranche S
    Union Med Can; 1995 Nov; 124(3):8-13. PubMed ID: 8560639
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of the newer antidepressants.
    Burke MJ; Harvey AT; Preskorn SH
    Am J Med; 1996 Jan; 100(1):119-21. PubMed ID: 8579077
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
    Preskorn S
    Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():13-9. PubMed ID: 7963446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
    Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
    Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertraline: a new antidepressant.
    Auster R
    Am Fam Physician; 1993 Aug; 48(2):311-4. PubMed ID: 8342482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Duan SX; Harmatz JS; Shader RI
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1278-83. PubMed ID: 8138941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
    Miller HL; Delgado PL; Salomon RM; Berman R; Krystal JH; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1996 Feb; 53(2):117-28. PubMed ID: 8629887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.